Inmune Bio Stock Investor Sentiment

INMB Stock  USD 5.05  0.16  3.27%   
About 72 percent of all INmune Bio's investors are curious in acquiring. The analysis of the overall investor sentiment regarding INmune Bio suggests that quite a large number of traders are confidant. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  

INmune Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards INmune Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at news.google.com         
Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN
Google News at Macroaxis
over a week ago at news.google.com         
INmune Bio stock hits 52-week low at 4.76 amid market challenges - Investing.com
Google News at Macroaxis
over two weeks ago at globenewswire.com         
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimers Dise...
Macroaxis News: globenewswire.com
over two weeks ago at finance.yahoo.com         
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimers Dise...
Yahoo News
over three weeks ago at finance.yahoo.com         
INmune Bio Third Quarter 2024 Earnings US0.60 loss per share
Yahoo News
over three weeks ago at simplywall.st         
Is INmune Bio Using Debt In A Risky Way?
Simply Wall St News at Macroaxis
over three weeks ago at insidermonkey.com         
INmune Bio, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
INmune Bio Inc Q3 2024 Earnings Call Highlights Navigating Financial Challenges and ...
Gurufocus Stories at Macroaxis
over three weeks ago at investing.com         
Earnings call INmune Bio Q3 2024 results show progress in clinical trials
Investing News at Macroaxis
over three weeks ago at globenewswire.com         
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
INmune Bio Inc Q3 2024 Earnings Report Preview What To Look For
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Acquisition by Tesi Raymond Joseph of 130000 shares of INmune Bio subject to Rule 16b-3
news
over a month ago at thelincolnianonline.com         
INmune Bio Scheduled to Post Quarterly Earnings on Thursday
news
over a month ago at finance.yahoo.com         
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Yahoo News
over a month ago at news.google.com         
Highbridge Capital Managements Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Moss David J of 7690 shares of INmune Bio at 6.4 subject to Rule 16b-3
09/12/2024
2
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
09/16/2024
3
Acquisition by Moss David J of 18028 shares of INmune Bio at 9.152 subject to Rule 16b-3
09/25/2024
4
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimers Disease
09/30/2024
5
INmune Bio Inc Q2 2024 Earnings Call Highlights Promising Advances Amid Rising Costs
10/09/2024
6
Insider Stock Buying Reaches US951.2k On INmune Bio
10/24/2024
7
Acquisition by Tesi Raymond Joseph of 130000 shares of INmune Bio subject to Rule 16b-3
10/29/2024
8
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
10/31/2024
9
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimers Disease
11/13/2024
10
Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN
11/20/2024

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets